Cagrilintide plus semaglutide: what 8 trials show and what’s next
News · Cagrilintide
A meta-analysis of 8 trials, a 7,076-person heart trial design and a rat study add detail to the cagrilintide-semaglutide picture, and leave open questions.

A new meta-analysis pools eight randomized trials and finds that pairing the amylin analogue cagrilintide with the GLP-1 receptor agonist semaglutide produced more weight and blood-sugar reduction than either drug alone, along with more side effects [1]. Two more reports add context. One describes a 7,076-person heart outcomes trial that has finished randomizing participants [2], and the other is a rat study that adds cagrilintide to a triple agonist [3]. Together they show how far the amylin-plus-GLP-1 approach has come, and how much is still unknown, especially about the heart and the long term.
Key takeaways
- A meta-analysis of 8 randomized trials (n=6,898) found greater weight, waist and HbA1c reductions with cagrilintide-semaglutide than with semaglutide, cagrilintide or placebo, but also more adverse events, mostly gastrointestinal [1].
- The difference in HbA1c compared with semaglutide alone was small (0.09 percentage points), and many outcomes showed very high variation between trials [1].
- A cardiovascular outcomes trial in 7,076 adults with established heart or blood vessel disease has published its design and baseline data, but it has not reported results [2].
- A study in obese male rats found that combining cagrilintide with retatrutide led to more weight loss than either drug alone. This is animal data and does not show what would happen in people [3].

The meta-analysis: eight trials pooled
What kind of study: a systematic review and pairwise meta-analysis of randomized controlled trials, using random-effects models [1]. The authors searched four major databases up to June 2026 and included eight trials with 6,898 adults who had overweight, obesity and/or type 2 diabetes [1].
What it found on weight: Compared with semaglutide alone, the combination was linked to an extra 6.6 percentage points of body weight reduction (95% CI 4.68 to 8.51) [1]. The gap was 8.15 points compared with cagrilintide alone and 14.3 points compared with placebo [1]. The combination also showed larger reductions in absolute body weight, waist circumference and body mass index against all comparators [1].
On blood sugar: HbA1c, a measure of average blood glucose, fell more with the combination than with each comparator [1]. The size of that advantage varied a great deal. It was 0.09 percentage points versus semaglutide, 0.87 versus cagrilintide and 1.55 versus placebo [1]. The difference versus semaglutide reached statistical significance, but it is small.
Other measures: Blood pressure results were better than with cagrilintide or placebo and similar to semaglutide [1]. C-reactive protein, a marker of inflammation, and blood lipids improved compared with cagrilintide and placebo [1].
Side effects: The combination increased both overall adverse events and gastrointestinal adverse events compared with every comparator, including each drug on its own [1].
Limits: The authors point to the small number of eligible trials and the lack of long-term cardiovascular endpoints [1]. Heterogeneity was substantial for several outcomes. The I² statistic reached 95% to 99% in some weight comparisons, which means the individual trials disagreed widely on effect size [1]. The authors trace this to differences in participants’ baseline characteristics and background therapies [1]. In practice, the pooled averages hide a lot of spread, and the size of any effect depends heavily on who was studied.
REDEFINE 3: a heart trial in progress
What kind of study: a double-blind, randomized, placebo-controlled cardiovascular outcomes trial. The new paper reports its design and baseline characteristics, not its results [2]. All participants also received standard care [2].
Who is in it: Between January 2023 and December 2024, 7,076 adults were randomized at 575 sites in 24 countries [2]. All had established cardiovascular disease and a BMI of 25 or higher, with or without type 2 diabetes [2]. Their mean age was 66 [2]. About 76% had a BMI of 30 or more, and 61% (n=4,348) had type 2 diabetes, with an average diabetes duration of 12 years [2]. Most participants (62%) had a prior heart attack, 19% had a prior stroke and 11% had peripheral arterial disease [2].
What it is testing: The safety goal is to show that the combination does not increase a composite of cardiovascular death, nonfatal heart attack or nonfatal stroke compared with placebo, a so-called noninferiority test [2]. The efficacy goal is to show that it lowers a broader composite that also includes revascularization procedures [2].
Limits: There are no outcome data yet [2]. The population is older, mostly people with a prior heart attack, and at high cardiovascular risk [2]. Results may not carry over to younger or lower-risk groups. The authors’ statement that the combination “could improve” outcomes is a hypothesis the trial is designed to test, not a finding [2].
The rat study: adding cagrilintide to a triple agonist
What kind of study: a preclinical study in diet-induced obese male rats [3]. The abstract does not give the number of animals. Retatrutide is a single molecule that activates three receptors (GLP-1, GIP and glucagon), and cagrilintide acts on amylin and calcitonin receptors [3]. Combined, the two drugs reach five receptor types [3].
What it found: Giving both drugs together reduced body weight and food intake in a dose-dependent way [3]. These reductions were larger than with either drug alone at equivalent amounts, and larger than comparison combinations that paired cagrilintide with semaglutide or tirzepatide [3]. The combination also improved blood cholesterol, triglycerides and insulin levels [3].
Pair-feeding and weight-matching experiments suggested that reduced eating alone did not explain the extra weight loss [3]. Profiling of blood proteins pointed to changes in energy-related processes, and brain gene-expression data identified shared neuronal programs tied to energy balance [3].
Limits: These are rat results, and they do not show what the combination would do in humans [3]. Only male animals were studied, so the findings say nothing about females [3]. Rat metabolism, drug handling and appetite regulation differ from those of people, and amounts used in rats do not translate directly to humans. The authors present the work as guidance for designing future multi-receptor molecules, not as evidence about any human use [3].
What else is underway
Two registry entries show where clinical research is heading. Neither has posted results.
- A phase 3 study is looking at weight loss and long-term maintenance of weight loss with the combination in people living with obesity. It is listed as active but no longer recruiting [4].
- A phase 3 study of cagrilintide and of the combination in children and adolescents with excess body weight is currently recruiting [5].
These entries describe planned research only, and their designs could change before results appear [4, 5].
What we still don’t know
- Heart outcomes: The meta-analysis had no long-term cardiovascular endpoints [1]. Whether the combination is neutral, helpful or harmful for heart attacks, strokes and cardiovascular deaths awaits REDEFINE 3 [2].
- Durability: It is unclear whether the weight and metabolic changes last over years and what happens to them over time. The long-term maintenance trial is designed to address part of this question [4].
- Who benefits most: The high heterogeneity across trials means average effects may not reflect any particular group [1]. Results in younger people are not yet available [5].
- Tolerability trade-offs: Gastrointestinal side effects were more common with the combination than with either drug alone [1]. How that balances against the extra effect over longer periods is not settled.
- The five-receptor idea in people: The cagrilintide-retatrutide findings come only from male rats [3]. No human data on this combination appear in these sources, so its effects and safety in people are unknown.
References
- Efficacy and Safety of [cagrilintide/semaglutide] for Metabolic Outcomes: Systematic Review and Pairwise Meta-Analysis of Randomized Controlled Trials. Diabetes, Metabolic Syndrome and Obesity (2026). doi:10.2147/DMSO.S616418
- Design and baseline characteristics of the [cagrilintide/semaglutide] cardiovascular outcomes trial (REDEFINE 3). American Heart Journal (2026). doi:10.1016/j.ahj.2026.107626
- Cagrilintide and retatrutide combination therapy enhances weight loss and metabolic outcomes in obese male rats. Nature Metabolism (2026). doi:10.1038/s42255-026-01603-y
- A Research Study to Look at How Well [cagrilintide/semaglutide] Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term. ClinicalTrials.gov NCT07011667, status: active not recruiting.
- A Research Study on How Well Cagrilintide and [cagrilintide/semaglutide] Work in Children and Adolescents With Excess Body Weight. ClinicalTrials.gov NCT07253285, status: recruiting.
Image credits
Free to use (CC0 / public domain); credited as a courtesy.